Dr. Ashish Jha, Brown School of Public Health, joins 'Closing Bell Overtime' to talk Novo Nordisk getting approval fro a Wegovy pill, sending its stock climbing.
Breakdown
- GLP-1 drugs are highly effective for obesity and related diseases 14s
- Oral GLP-1 drugs increase accessibility for those avoiding injections 41s
- Novo Nordisk is first to market; Eli Lilly expected to follow soon 1m 5s
- Initial healthcare costs will rise, but long-term health benefits expected 2m 8s
- Widespread GLP-1 use could help people live longer, healthier lives 2m 56s